



**Scientist / Associate Scientist, Cancer Immunotherapy
(Stealth)
Job code 477RM**

Description

Fate Therapeutics is seeking a highly motivated individual with expertise in cancer immunology and/or allogeneic adoptive cell transfer biology to join a multidisciplinary team dedicated to the discovery of novel cellular therapeutics for the treatment of cancer. We welcome candidates with a high level of proficiency in mammalian cell culture and a practical understanding of effector cell biology. In addition, experience with allogeneic models of rejection including MLR, graft-vs-host disease, transplant immunology, or related fields is beneficial. Familiarity with current molecular biology techniques used for gene-editing and protein engineering of lymphocytes are desirable. This position will be a key member of our cancer immunotherapy team and will assist in the differentiation of iPSC-derived T and NK cells, in addition to the execution of in vitro and in vivo studies that test Fate Therapeutics' novel cellular therapy products. The selected candidate also has the opportunity to participate in ongoing collaborations with top academic investigators and prominent pharmaceutical partners to develop novel immune-evasion strategies. This is a full-time, bench-level position reporting to a Scientist in Cancer Immunotherapy and is located at the Company's corporate headquarters in San Diego, California.

Responsibilities

- Differentiation and culture of iPSC-derived T and NK cells using defined research protocols
- Isolation and expansion of peripheral blood NK cells using defined research protocols
- Assessment of T and NK cell phenotype using multi-parameter flow cytometry
- Assessment of iPSC-derived NK cell function using standard in vitro assays that measure proliferation, cytokine secretion, and target cell killing
- Execution of in vitro and in vivo allogeneic rejection models including MLRs and NK cell cytotoxicity assays
- Support programs at Fate in the areas of tumor immunology and cellular immunotherapies
- Present data to immunology groups and larger program-specific teams

Qualifications

- PhD degree in Immunology, Cell Biology or related fields with a minimum of one year postdoctoral experience in Immunology, Cell Biology or related fields (Scientist level), or BS/MS with a minimum of five years of relevant laboratory experience, preferably in a mid-stage biotech, or pharmaceutical setting (Associate Scientist level)
- In-depth experience with multi-parameter flow cytometry
- In-depth experience in mammalian cell culture
- In-depth experience in executing and developing assays for primary human T or NK cells
- In-depth experience in processing animal samples
- Experience with IncuCyte and/or xCELLigence platforms is a plus
- Experience with current molecular biology techniques for editing and engineering of T cells and NK cells is a plus



- Proven ability to coordinate with multiple researchers for scheduling and execution of complex experiments
- Excellent communication and organization skills are essential
- Positive outlook and a team-oriented attitude

Working Conditions and Physical Requirements

- Will require working with cells and cell lines of human and/or animal origin
- Will require working with hazardous materials
- 100% on-site work at corporate headquarters in San Diego, CA
- Evening and weekend work as necessary

The preceding job description indicates the general nature and level of work performed by employees within this classification. Additional and incidental duties related to the primary duties may be required from time to time.

For consideration send cover letter and resume to: careers@fatetherapeutics.com and reference job code 477RM.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). The Company's pipeline also includes ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease in patients with hematologic malignancies undergoing allogeneic stem cell transplant. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.